Now approved

ULTOMIRIS is not used in treating people with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS).

ULTOMIRIS is the first and only long-acting complement inhibitor for atypical-HUS that provides immediate and complete C5 inhibition sustained for up to 8 weeks.*

*Starting 2 weeks after the initial loading dose, maintenance doses are administered once every 4–8 weeks.

For patients:
Are you ready to start or transition?

OneSource™ is here to help. OneSource is a personalized patient support program staffed by Alexion Case Managers, all of whom are registered nurses with extensive clinical experience—giving you the support you need when starting a new treatment prescribed by your healthcare provider.

Join OneSource

Download the OneSource enrollment form

Need more information before starting ULTOMIRIS?

Download our patient brochure, which will give you valuable information about this long-acting treatment, including how it works, how you take it, and what to expect.

Patient brochure

Talk to your doctor about starting ULTOMIRIS today!

For healthcare professionals:
Support to help start or transition patients

Get the information you need to start or transition your patient and get detailed instructions on how to administer ULTOMIRIS.

Explore the ULTOMIRIS REMS program

Dosing and administration guide

Sign up to learn more about ULTOMIRIS.

Please select one:

ALL FIELDS REQUIRED

*Required fields
Thank you for subscribing

We have successfully received your subscription request.
You’ll see one of our emails arriving in your inbox sometime soon.